Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Onkure Therapeutics Inc OKUR

Healthcare Biotechnology
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the... see more

Recent & Breaking News (NDAQ:OKUR)

OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies

GlobeNewswire March 27, 2026

OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

GlobeNewswire March 12, 2026

OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update

GlobeNewswire November 6, 2025

OnKure Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire November 4, 2025

OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

GlobeNewswire August 12, 2025

OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

GlobeNewswire May 6, 2025

OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

GlobeNewswire March 10, 2025

OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences

GlobeNewswire March 4, 2025

OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219

GlobeNewswire December 10, 2024

OnKure Announces New Date for Upcoming Investor Call

GlobeNewswire November 25, 2024

OnKure to Present at the Stifel 2024 Healthcare Conference

GlobeNewswire November 5, 2024

OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium

GlobeNewswire November 1, 2024

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

GlobeNewswire October 4, 2024

Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure

GlobeNewswire October 2, 2024

RPHM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Reneo Pharmaceuticals, Inc. Is Fair to Shareholders

Business Wire September 3, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VAPO, SGE, RPHM, SQSP on Behalf of Shareholders

PR Newswire August 29, 2024

RENEO PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM

Business Wire August 29, 2024

Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results

GlobeNewswire August 13, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RPHM, VAPO, PRFT on Behalf of Shareholders

PR Newswire July 1, 2024

Kuehn Law Encourages INFN, RPHM, VAPO, and PRFT Investors to Contact Law Firm

PR Newswire July 1, 2024

Podcasts